CUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03.
Published April 1, 2026 · Recall initiated: March 17, 2026
Summary
FDA records drug Class II recall D-0402-2026, published April 1, 2026 and initiated March 17, 2026. Recalling firm: Chiesi USA, Inc.; Status: Ongoing; Reported quantity: 7,235 vials; Lot: Lot #: 1213748, Exp. Date 09/2026; 1215076, 1215077, Exp. Date 10/26. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility
What to do
Voluntary: Firm initiated · Letter
Get an email if CUROSURF has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- CUROSURF
- Manufacturer
- Chiesi USA, Inc.
- Distributor
- Nationwide within the United States
- Lot
- Lot #: 1213748, Exp. Date 09/2026; 1215076, 1215077, Exp. Date 10/26.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAGelatin Capsule Pack for use with the Sodium Iodide I-131 Kit (containing 5 empty capsules and 5 DibasicApril 1, 2026
- FDALevothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA,April 1, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial inApril 1, 2026
- FDAOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial inApril 1, 2026
- FDAProduct label reads in part as "WHITE VEIN ADVANCED ALKALOIDS CHEWABLE TABLETS 225mg 7-Hydroxymitragynine perMarch 25, 2026
- FDAProduct label reads in part as "WHITE VEIN ADVANCED ALKALOIDS CHEWABLE TABLETS 15mg 7-Hydroxymitragynine perMarch 25, 2026
Questions about this recall
Was CUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03. recalled?
Yes. FDA published recall D-0402-2026 on April 1, 2026. Reported hazard: Lack of Assurance of Sterility
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: CUROSURF.